| Useful Advices |
Hubs | Hubbers | Topics | Request |
| #1 in Business | Subscribe Email Print |
|
You are here: Home > Business > Business > Business Brokers and Valuations, a Comment |
|
Useful Advices - Business Brokers and Valuations, a Comment
Business Brokers often double as business appraisers. I see a real problem with business brokers and their valuations teams it se According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product ems like a huge conflict of interest to me. Many times the business broker sales person is also a licensed business evaluator. B ; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug. Examples of combination products may in ut the job should be done by a CPA or a non-involved “Certified Business Appraiser” and not the same Business Broker making the l lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together. isting for the sale of that business. See: http://www.cpa2biz.com Other books on this subject I found relevant are: “A CPAs Gu here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe ide to Valuing a Closely Held Business” by Gary Trugman. “The Value Reporting Revolution: Moving Beyond the Earnings Game” by Ro d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations. Combination pro bert Eccles. One should find it ironic that a sales man for a business broker company can tell a prospect anything he wants to a ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc nd then in the purchase agreement and even the deposit agreement from the buyer have a clause in the contract that says something easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi to the effect that you have done your due diligence and nothing we have said verbally or in writing was used to affect your decis nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically ion. As a franchisor I take issue with these things. You see these same business brokers have all kinds of web sites, which they and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ charge franchisors to be on to sell their franchises. Yet a franchisor cannot do the same thing due to regulations, then the bu ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi siness brokers charge the franchisor one half the franchise fee for a commission. Very questionable activity as was also talked ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it. Following aspects would a about in the Journal of Accountancy, not about franchises but about real evaluations. I have seen accountant students sitting in dd to the challenges in developing combination products: Which markets to tap where the combination products can do fairly well? Which combination prod Borders Caf? studying their rather large text books on the subject and also heard horror stories from bankers of under evaluatin cts are meaningful and rational? Which therapeutic categories to select? Which Combinations can address unmet needs of the patients? Do combin g businesses, business brokers under valuating when working for the seller and over evaluating when working for the buyer; all in tions increase the patient compliance? What would be the developing cost? How to tackle the risks encountered during combination product developmen order to secure the commission and make the sale. This sort of incentive yields abuses and cheating in the game. Similarly the re t? As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel al estate agent who hires an appraiser knows those who are heavy-handed evaluators and uses them to her advantage when needed. T ping new procedures for reviewing their safety, efficacy and quality. Professional from academic institutions, pharmaceutical industries, health care indust he truth is anything is only worth what someone will pay you for it. Accountants, many of them are crooks out right, while many y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products of them are simply doing business as usual while everyone else pays for their little sins. All these people, humans who hold the . As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de mselves out as professionals are simply doing what this species is very much known for; taking advantage of a situation for their elopment. They need to be wiser in analyzing the market trends and the regulatory requirements. Companies that provide selfless information through particip own personal gain. We need to have adequate rules which reward honesty, but all we have is attorneys making rules? Think on this tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
Related Articles:They Laughed When I Told Them About This Factors Which Affect the Overall Value of a Business
|